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Chun-Yu Liu1,2,3,4†, Ling-Ming Tseng2,5†, Jung-Chen Su1, Kung-Chi Chang1,3,4, Pei-Yi Chu6, Wei-Tien Tai7,8,
Chung-Wai Shiau1* and Kuen-Feng Chen7,8*Erratum
In the published article [1], the authors noticed an error
to Fig. 1e in which the MTT curve of drug treatments
(sorafenib, SC-1 and SC-43) in SK-BR3 cells was
erroneously put as the same with that of HCC-1937 cells.
The correct version of Fig. 1 (including correct Fig. 1e)
is included in this erratum.
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Fig. 1 SC-1 and SC-43, without effects on raf-1 kinase activity, show more potent anti-proliferative activity than sorafenib in breast cancer cells. a
chemical structures of sorafenib, SC-1 and SC-43. b effects of sorafenib, SC-1 and SC-43 on Raf-1 activity in MDA-MB-231 cells. Columns,
mean (n = 3); bars, SD; *P <0.05 compared to control. c effects of sorafenib, SC-1 and SC-43 on the phosphorylation of ERK1/2, VEGFR2
and PDGFRβ in MDA-MB-231cells. Cells were exposed to sorafenib, SC-1 or SC-43 at 1 and 5 μM for 12 hours. Data are representative of
three independent experiments. d effects of sorafenib, SC-1 and SC-43 on the phosphorylation of STAT3 upstream kinases JAK1 and JAK2
in MDA-MB-231 (Left) and MDA-MB-468 cells (Right). Cells were exposed to sorafenib, SC-1 or SC-43 at 1 and 5 μM for 12 hours. Data
are representative of three independent experiments. e dose-escalation effects of sorafenib, SC-1 and SC-43 on cell viability in six breast
cancer cell lines. Cells were exposed to sorafenib, SC-1 or SC-43 at the indicated doses for 48 hours and cell viability was assessed by
the MTT assay. Points, mean (n = 3); bars, SD. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
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